The proposed study was formulated in response to RFA HL-98-012 requesting applications to investigate cardiovascular complications from cocaine abuse in HIV infection, with a focus on the call for clinical studies to identify effective treatment protocols. Cocaine use by HIV-positive individuals represents a primary vector of infection to non-infected individuals, and may also adversely affect disease progression, including increasing risk for cardiovascular dysfunction. A treatment approach targeting both cocaine use and cardiovascular disorders simultaneously would therefore be extremely beneficial in an HIV- positive, cocaine-abusing patient population. The proposed study capitalizes on the multiple effects of the angiotensin converting enzyme (ACE) inhibitor, fosinopril, in numerous tissue systems, and will investigate its ability to reduce cocaine use through activity in the brain, and to reverse or prevent the cardiotoxic effects of cocaine and HIV disease by actions upon the heart and cardiovascular system, including platelet aggregation factors. In the proposed five-year study, one hundred and twenty-four HIV- positive cocaine-dependent methadone-maintained patients will be randomly assigned to receive either fosinopril (20 mg/day) or placebo for six months.
The specific aims of this study are: (a) to investigate the efficacy of fosinopril for the treatment of cocaine dependence in HIV-positive methadone-maintained patients, based on twice weekly urine toxicology screens; (b) to determine the ability of fosinopril to improve cardiac functioning by comparing pre- and post-treatment two-dimensional and Doppler echocardiograms, and (c) to investigate the ability of fosinopril to decrease platelet reactivity to physiological agonists. Biological and psychosocial risk factors for cardiovascular disorders (including CD4 count, viral load, antiretroviral medications, family history of cardiovascular disease, severity of addiction, depression, and subjective cardiovascular distress during cocaine use) will also be examined.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA012776-05
Application #
6634281
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (F2))
Program Officer
Khalsa, Jagjitsingh H
Project Start
1999-06-15
Project End
2005-05-31
Budget Start
2003-06-01
Budget End
2005-05-31
Support Year
5
Fiscal Year
2003
Total Cost
$299,076
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520